Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology granted 48,450 inducement stock options to four new hires at a $12.89 exercise price, vesting over four years.

Rhea-AI Summary

Kura Oncology (KURA) granted inducement stock options for 48,450 shares to four new employees on September 1, 2026, under its 2023 Inducement Option Plan. The awards were approved by the Board’s Compensation Committee as inducements to employment in line with Nasdaq Listing Rule 5635(c)(4).

Each option has an exercise price of $12.89 per share, equal to the closing price on the grant date, and vests over four years: 25% after one year, with the remaining shares vesting monthly over the following 36 months, subject to continued service. The options are governed by the 2023 Inducement Option Plan and individual option agreements. Kura develops precision oncology medicines, including FDA-approved KOMZIFTI (ziftomenib) for relapsed or refractory NPM1-mutated acute myeloid leukemia.

News Explained

The September 1 awards are options to purchase 48,450 shares, not a current issuance; any ownership dilution would require later exercise and share issuance, while four-year vesting makes the potential increase conditional on continued service.

Market Context

KURA closed at $13.15 before publication, while the August 7 inducement-grant event produced a 3.13%...

Analysis

KURA closed at $13.15 before publication, while the August 7 inducement-grant event produced a 3.13% 24-hour move. The platform record adds a prior grant precedent and recent net buying; future filings may clarify additional equity awards.

Key Figures

Option shares: 48,450 shares Recipients: 4 employees Exercise price: $12.89 per share +5 more

8 metrics

Option shares 48,450 shares Inducement awards granted to four new employees

Recipients 4 employees New employees receiving inducement awards

Exercise price $12.89 per share Equal to the September 1, 2026 closing price

Vesting period 4 years Option vesting schedule

Initial vesting 25% Underlying shares vesting on the one-year anniversary

Subsequent vesting 36 months Balance vesting monthly after the one-year anniversary

Listing rule Nasdaq Listing Rule 5635(c)(4) Employment inducement approval basis

Grant date September 1, 2026 Date the Compensation Committee granted the awards

Historical Context

5 past events · Latest: Sep 01 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Sep 01	Investor conferences	Neutral	+1.9%	Management announced participation in three September healthcare investor conferences.
Aug 12	Second-quarter earnings	Positive	+1.5%	Commercial ramp and collaboration revenue accompanied second-quarter financial results.
Aug 10	Preclinical publication	Positive	+2.9%	Blood publication detailed ziftomenib binding and preclinical leukemia-model activity.
Aug 07	Inducement option grants	Neutral	+3.1%	Options covering 104,500 shares were granted to six new employees.
Aug 05	Earnings-date notice	Neutral	-2.9%	The company scheduled its second-quarter financial results for August 12.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent substantive company reports were followed by positive 24-hour reactions, while scheduling and prior inducement-grant notices showed less consistent alignment.

Key Terms

nonstatutory stock options, inducement awards, nasdaq listing rule 5635(c)(4)

3 terms

nonstatutory stock options financial

"granted inducement awards consisting of nonstatutory stock options to purchase"

A nonstatutory stock option is a company-issued right that lets an employee or contractor buy shares later at a set price, but it does not qualify for special tax breaks. Think of it like a voucher to buy stock at today’s price; when used, the difference between market price and voucher price is taxed as ordinary income to the holder. Investors care because these options create potential share dilution, affect reported compensation costs, and influence employee incentives and cash flow when taxes and withholdings are settled.

inducement awards financial

"granted inducement awards consisting of nonstatutory stock options"

Inducement awards are special bonuses given to new employees to encourage them to join a company, often in the form of stock or money. They matter because they can motivate talented people to choose one company over another and help align their success with the company's growth. Think of it like a signing bonus to seal the deal.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on September 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 48,450 shares of common stock to four (4) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option has an exercise price equal to $12.89 per share, the closing price of the Company’s common stock on September 1, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant.

About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI^® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.

Kura Contact

Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com

FAQ

What inducement stock option grants did Kura Oncology (KURA) announce on September 4, 2026?

Kura Oncology announced that its Compensation Committee granted inducement nonstatutory stock options to purchase 48,450 shares of common stock to four new employees on September 1, 2026, under the company’s 2023 Inducement Option Plan, as amended.

What is the exercise price of the new Kura Oncology (KURA) inducement stock options?

Each inducement stock option granted by Kura Oncology has an exercise price of $12.89 per share, which equals the closing price of the company’s common stock on September 1, 2026, the grant date.

How do the Kura Oncology (KURA) inducement stock options vest for the new employees?

The inducement stock options vest over four years: 25% of the underlying shares vest on the one-year anniversary of the vesting commencement date, and the remaining shares vest monthly over the following 36 months, subject to continued service.

Under which plan were the new Kura Oncology (KURA) inducement options granted?

The new inducement stock options were granted under Kura Oncology’s 2023 Inducement Option Plan, as amended, and are also subject to the terms and conditions of individual stock option agreements covering each grant.

What cancer therapy does Kura Oncology (KURA) currently commercialize?

Kura Oncology developed and is commercializing KOMZIFTI (ziftomenib), an FDA-approved once-daily oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia.